{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T15:31:22Z","timestamp":1767713482248,"version":"3.46.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.euf.2025.06.016","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:23:47Z","timestamp":1753903427000},"page":"863-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of the Stockholm3 Test in Guiding Confirmation Biopsy Decisions for Patients with Prostate Cancer on Active Surveillance"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7020-0276","authenticated-orcid":false,"given":"Serdar","family":"Madendere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mert","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhan","family":"Palao\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mert","family":"Veznikli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metin","family":"Vural","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ay\u015fenur","family":"\u0130\u011fdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tar\u0131k","family":"Esen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Balbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.06.016_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.06.016_b0010","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.eururo.2015.06.012","article-title":"Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers","volume":"68","author":"Bokhorst","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.06.016_b0015","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/life14010076","article-title":"A systematic review on prostate-specific membrane antigen positron emission tomography (PSMA PET) evaluating localized low- to intermediate-risk prostate cancer: a tool to improve risk stratification for active surveillance?","volume":"14","author":"Liu","year":"2024","journal-title":"Life"},{"key":"10.1016\/j.euf.2025.06.016_b0020","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.euo.2023.07.006","article-title":"Results from the PRIMA trial: comparison of the STHLM3 test and prostate-specific antigen in general practice for detection of prostate cancer in a biopsy-na\u00efve population","volume":"6","author":"Freds\u00f8e","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.06.016_b0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2017.12.028","article-title":"The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential","volume":"74","author":"Str\u00f6m","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.06.016_b0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euf.2024.07.009","article-title":"External validation of Stockholm3 in a retrospective German clinical cohort","volume":"11","author":"Tilki","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2025.06.016_b0035","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.3390\/cancers13174251","article-title":"Biomarker in active surveillance for prostate cancer: a systematic review","volume":"13","author":"Manceau","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2025.06.016_b0040","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.juro.2012.06.009","article-title":"Association of [\u22122]proPSA with biopsy reclassification during active surveillance for prostate cancer","volume":"188","author":"Tosoian","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.06.016_b0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/pcan.2017.3","article-title":"ProPSA and the Prostate Health Index as predictive markers for aggressiveness in low-risk prostate cancer-results from an international multicenter study","volume":"20","author":"Heidegger","year":"2017","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.06.016_b0050","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.juro.2018.08.047","article-title":"Genomic prostate score, PI-RADS\u2122 version 2 and progression in men with prostate cancer on active surveillance","volume":"201","author":"Kornberg","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2025.06.016_b0055","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41391-022-00538-1","article-title":"Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis","volume":"25","author":"Sari Motlagh","year":"2022","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.06.016_b0060","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pros.24621","article-title":"The role of PSMA PET\/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer","volume":"84","author":"Esen","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.euf.2025.06.016_b0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bju.13836","article-title":"Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer","volume":"120","author":"Alberts","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.06.016_b0070","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bju.15065","article-title":"Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?","volume":"126","author":"Osses","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.06.016_b0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41391-022-00582-x","article-title":"Risk of progression following a negative biopsy in prostate cancer active surveillance","volume":"26","author":"Beckmann","year":"2023","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.euf.2025.06.016_b0080","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.clgc.2021.09.007","article-title":"The impact of visible tumor (PI-RADS\u00a0\u2265\u00a03) on upgrading and adverse pathology at radical prostatectomy in low risk prostate cancer patients: a biopsy core based analysis","volume":"20","author":"\u00d6zkan","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2025.06.016_b0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euros.2021.11.006","volume":"35","author":"Olivier","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.06.016_b0090","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.euo.2022.03.007","article-title":"A multivariable approach using magnetic resonance imaging to avoid a protocol-based prostate biopsy in men on active surveillance for prostate cancer\u2014data from the international multicenter prospective PRIAS study","volume":"5","author":"Luiting","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2025.06.016_b0095","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/jnci\/djaa131","article-title":"Incorporating magnetic resonance imaging and biomarkers in active surveillance protocols \u2013 results from the prospective Stockholm3 active surveillance trial (STHLM3AS)","volume":"113","author":"Olsson","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euf.2025.06.016_b0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.euf.2016.11.016","article-title":"Balancing overdiagnosis and early detection of prostate cancer using the Stockholm-3 model","volume":"4","author":"Nordstr\u00f6m","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"5 Suppl","key":"10.1016\/j.euf.2025.06.016_b0105","article-title":"MP36-11 The role of the Stockholm 3 test before confirmatory biopsies for prostate cancer patients enrolled in active surveillance: results from the STHLM3 AS NorDCaP study","volume":"213","author":"Giudici","year":"2025","journal-title":"J Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T22:13:04Z","timestamp":1765404784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925001816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2405456925001816"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.06.016","relation":{},"ISSN":["2405-4569"],"issn-type":[{"type":"print","value":"2405-4569"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of the Stockholm3 Test in Guiding Confirmation Biopsy Decisions for Patients with Prostate Cancer on Active Surveillance","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}